NCT03080051

Who might be able to join this trial:

For everyone:

• You must be willing and able to sign a consent form before any part of the study begins.
• Women must either be surgically sterile (e.g., had a hysterectomy, both ovaries removed, or tubes tied), be post-menopausal for at least 1 year, or agree to use a barrier method of contraception (such as condoms) throughout the study.
• Men and their partners who could become pregnant must agree to use two forms of contraception, one of which must be a barrier method, for the whole study.
• Men must not donate sperm during the study and for 90 days after it ends.
• You must be willing and able to take part in all study procedures.

For healthy volunteers:

• You must be male or female and under 55 years old.
• You must be in good health with no significant findings on a physical check-up.
• You must have no problems with your nervous system, as assessed by the study doctor.
• You must have no family history of Alzheimer's disease or any brain disease linked to dementia.
• You must score 0 on a memory and thinking assessment called the CDR (confirm with trial site).

For people diagnosed with probable Alzheimer's disease (AD):

• You must be male or female, aged between 50 and 90 years old.
• You must have a diagnosis of probable Alzheimer's disease based on recognised medical guidelines.
• You must score 0.5 or higher on a memory and thinking scale called the CDR (confirm with trial site).
• You must score 28 or below on a standard memory test called the MMSE (confirm with trial site).
• A specific brain scan (PET scan) must show signs of amyloid protein build-up in your brain.
• A brain MRI scan must be consistent with an Alzheimer's diagnosis and show no other causes for your symptoms.
• If you take medication for Alzheimer's symptoms, your dose must have been stable for at least 30 days before the study screening.
• You must have a carer who can accompany you to visits if needed.
• You (and/or your legal representative or carer, if applicable) must sign and date a consent form.

For people diagnosed with probable Progressive Supranuclear Palsy (PSP):

• You must be male or female, aged between 50 and 90 years old.
• You must have a clinical diagnosis of PSP based on recognised medical guidelines.
• A specific brain scan (DaTSCAN SPECT) must show signs consistent with PSP in your brain (confirm with trial site).
• A brain MRI scan must be consistent with a PSP diagnosis and show no other concerning findings.
• If you take medication for PSP symptoms, your dose must have been stable for at least 30 days before screening.
• You must have a carer who can accompany you to visits if needed.
• You and your legal representative or carer must sign and date a consent form.

Who may not be able to join:

• You have a current or past history of alcohol or drug misuse.
• Your blood or lab test results show significant abnormalities, or you have a serious unstable medical condition.
• You have taken part in a study involving an experimental drug or device within the last 30 days.
• Your exposure to radiation from previous research or medical procedures in the past year has already reached the maximum safe annual level allowed by US guidelines.
• You are pregnant, breastfeeding, or currently lactating.
• You have a significant active condition affecting your digestive system, heart, liver, kidneys, blood, hormones, immune system, lungs, or another serious disorder (confirm with trial site).
• Your veins are not suitable for repeated blood draws.
• Your MRI scan shows certain types of brain abnormalities, such as significant evidence of stroke, infection, tumours, fluid build-up on the brain, or other serious brain conditions (confirm with trial site for specific details).
• You have certain implanted medical devices (such as a pacemaker, insulin pump, cochlear implant, or nerve stimulator) that are not certified as safe for MRI, or you have a history of severe claustrophobia in MRI scanners.

For people with Alzheimer's disease only:

• You have received any treatment specifically targeting amyloid-beta